

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shawn Shui-on LEUNG
Title: Framework-Patched Immunoglobulins
Appl. No.: 09/892,613
Filing Date: June 27, 2001
Examiner: David BLANCHARD
Art Unit: 1643
Atty Docket No: SBL-001US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP RCE
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits after the filing of a request for continued examination under § 1.114. Accordingly, no certification or fee is required.

To the extent required, copies of the cited references are enclosed herewith. However, to the extent that copies of U.S. patents and published patent applications are not required, they have not been provided.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: June 26, 2007

By: /chalin a. smith/

SMITH PATENT CONSULTING, LLC
3309 Duke Street
Alexandria, VA 22314

Name: Chalin A. Smith
Title: Attorney for Applicant
Registration No. 41,569

Tel: 703-549-7691
Fax: 703-549-7692

CUSTOMER NUMBER 31496

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. SBL-001US		SERIAL NO. 09/892,613	
				APPLICANT Shawn Shui-on LEUNG			
				FILING DATE June 27, 2001		GROUP 1643	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,789,554	08/04/98	Leung et al.	---	---		
	5,859,205	01/12/99	Adair et al.	---	---		
	6,187,287	02/13/01	Leung et al.	---	---		
	6,632,927	10/14/03	Adair et al.	---	---		
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes No	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Hamilton, Anita et al., "A Humanized Antibody against Human Cytomegalovirus (CMV) gpUL75 (gH) for Prophylaxis or Treatment of CMV Infections", Journal of Infectious Diseases, vol. 176:59-68 (1997)						
	Leung, Shui-on et al., "Construction and Characterization of a Humanized, Internalizing, B-Cell (CD-22)-Specific Leukemia/Lymphoma Antibody, LL2", Molecular Immunology, vol. 32(17/18): 1413-1427 (1995)						
	Reichmann, Lutz et al., "Reshaping Human Antibodies for Therapy", Nature, vol. 332: 323-327 (March 1988)						
	Rosok, Mae Joanne et al., "A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab", Journal of Biological Chemistry, vol. 271(37): 22611-22618 (September 1996)						
	Shan, Daming et al., "Characterization of scFV-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths", Journal of Immunology, vol. 162: 6589-6595 (1999)						
	Shearman, Clyde et al., "Construction, Expression, and Characterization of Humanized Antibodies Directed Against the Human α/β TCell Receptor", Journal of Immunology, vol. 147 (12): 4366-4373 (December 1991)						
	Wu, Tai Te, "From Esoteric Theory to Therapeutic Antibodies", Applied Biochem and Biotech, vol. 47: 107-118 (1994)						
	Zhengxing, Qu et al., "Humanization of Immu31, an α -Fetoprotein-specific Antibody", Clinical Cancer Research, vol. 5 (Suppl.):3095s-3100s (October 1999)						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.